# Research on Benefit of Umooze as Add- on Therapy in Benign Prostatic Hyperplasia

> **NCT02313233** · NA · COMPLETED · sponsor: **Golden Biotechnology Corporation** · enrollment: 41 (actual)

## Conditions studied

- Benign Prostatic Hyperplasia

## Interventions

- **DIETARY_SUPPLEMENT:** Umooze
- **DIETARY_SUPPLEMENT:** Placebo

## Key facts

- **NCT ID:** NCT02313233
- **Lead sponsor:** Golden Biotechnology Corporation
- **Sponsor class:** INDUSTRY
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-12
- **Primary completion:** 2015-05
- **Final completion:** 2015-05
- **Target enrollment:** 41 (ACTUAL)
- **Last updated:** 2016-06-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02313233

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02313233, "Research on Benefit of Umooze as Add- on Therapy in Benign Prostatic Hyperplasia". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02313233. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*